Additionally, they are not suitable for individuals with a history of severe pancreatitis, gallbladder disease, or those who are currently pregnant, planning to become pregnant, or breastfeeding
What are the management options for injection site reactions from tirzepatide (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist)?
The role of other factors in pathomechanism of IR is also under investigation
If youre just starting your GLP-1 medication, closely follow your titration schedule to help reduce side effects and support safer, more sustainable weight loss
A little more fiber, a little more water, and some patience go a long way
Week 36: Initial Weight Loss Begins Patients often begin losing 13 lbs per week once they reach a therapeutic dose